Update on twice-daily bromfenac sodium sesquihydrate to treat postoperative ocular inflammation following cataract extraction

Ester Carre&ntilde;o1, Alejandro Portero2, David J Galarreta1,3, Jos&eacute; M Herreras1,31Ocular Immunology Unit-IOBA (Instituto Universitario de Oftalmobiolog&iacute;a), University of Valladolid, Campus Miguel Delibes, Valladolid, Spain; 2Ocular Immunology Unit, Hospital La...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Carre&ntilde;o E, Portero A, Galarreta DJ, Herreras JM
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2012
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/76a71724af06481d95da14649eac9ae1
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:76a71724af06481d95da14649eac9ae1
record_format	dspace
spelling	oai:doaj.org-article:76a71724af06481d95da14649eac9ae12021-12-02T00:10:12ZUpdate on twice-daily bromfenac sodium sesquihydrate to treat postoperative ocular inflammation following cataract extraction1177-54671177-5483https://doaj.org/article/76a71724af06481d95da14649eac9ae12012-04-01T00:00:00Zhttp://www.dovepress.com/update-on-twice-daily-bromfenac-sodium-sesquihydrate-to-treat-postoper-a9771https://doaj.org/toc/1177-5467https://doaj.org/toc/1177-5483Ester Carre&ntilde;o1, Alejandro Portero2, David J Galarreta1,3, Jos&eacute; M Herreras1,31Ocular Immunology Unit-IOBA (Instituto Universitario de Oftalmobiolog&iacute;a), University of Valladolid, Campus Miguel Delibes, Valladolid, Spain; 2Ocular Immunology Unit, Hospital La Zarzuela, Madrid, Spain; 3Ocular Immunology Unit, Hospital Cl&iacute;nico Universitario de Valladolid, Valladolid, SpainAbstract: Ophthalmic bromfenac sodium sesquihydrate is a topically applied selective cyclooxygenase (COX)-2 inhibitor. It is similar to amfenac, except for a bromine atom at the C4 of the benzoyl ring position, which markedly affects its in vitro and in vivo potency, extends the duration of anti-inflammatory activity, and enhances its inhibitory effect on COX-2 absorption across the cornea and penetration into ocular tissues. The United States Food and Drug Administration approved bromfenac in 2005 for the treatment of postoperative inflammation and the reduction of ocular pain in patients who have undergone cataract surgery. Nonsteroidal anti-inflammatory drugs (NSAIDs), and among them bromfenac, could be even more effective than steroids at reestablishing the blood&ndash;aqueous barrier, as revealed by flare on slit-lamp examination and as quantitatively measured using ocular fluorophotometry. Similar to other NSAIDs, it has a role in inhibiting intraoperative miosis during cataract surgery. However, bromfenac also seems to be useful in other situations, such as refractive surgery, allergic conjunctivitis (not useful in dry eye), choroidal neovascularization, and even ocular oncology. No reports of systemic toxicity have been published and bromfenac has good topical tolerance with a low incidence of adverse effects.Keywords: bromfenac, ophthalmic nonsteroidal anti-inflammatory drugs, inflammation, cataract surgeryCarre&ntilde;o EPortero AGalarreta DJHerreras JMDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2012, Iss default, Pp 637-644 (2012)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ophthalmology RE1-994
spellingShingle	Ophthalmology RE1-994 Carre&ntilde;o E Portero A Galarreta DJ Herreras JM Update on twice-daily bromfenac sodium sesquihydrate to treat postoperative ocular inflammation following cataract extraction
description	Ester Carre&ntilde;o1, Alejandro Portero2, David J Galarreta1,3, Jos&eacute; M Herreras1,31Ocular Immunology Unit-IOBA (Instituto Universitario de Oftalmobiolog&iacute;a), University of Valladolid, Campus Miguel Delibes, Valladolid, Spain; 2Ocular Immunology Unit, Hospital La Zarzuela, Madrid, Spain; 3Ocular Immunology Unit, Hospital Cl&iacute;nico Universitario de Valladolid, Valladolid, SpainAbstract: Ophthalmic bromfenac sodium sesquihydrate is a topically applied selective cyclooxygenase (COX)-2 inhibitor. It is similar to amfenac, except for a bromine atom at the C4 of the benzoyl ring position, which markedly affects its in vitro and in vivo potency, extends the duration of anti-inflammatory activity, and enhances its inhibitory effect on COX-2 absorption across the cornea and penetration into ocular tissues. The United States Food and Drug Administration approved bromfenac in 2005 for the treatment of postoperative inflammation and the reduction of ocular pain in patients who have undergone cataract surgery. Nonsteroidal anti-inflammatory drugs (NSAIDs), and among them bromfenac, could be even more effective than steroids at reestablishing the blood&ndash;aqueous barrier, as revealed by flare on slit-lamp examination and as quantitatively measured using ocular fluorophotometry. Similar to other NSAIDs, it has a role in inhibiting intraoperative miosis during cataract surgery. However, bromfenac also seems to be useful in other situations, such as refractive surgery, allergic conjunctivitis (not useful in dry eye), choroidal neovascularization, and even ocular oncology. No reports of systemic toxicity have been published and bromfenac has good topical tolerance with a low incidence of adverse effects.Keywords: bromfenac, ophthalmic nonsteroidal anti-inflammatory drugs, inflammation, cataract surgery
format	article
author	Carre&ntilde;o E Portero A Galarreta DJ Herreras JM
author_facet	Carre&ntilde;o E Portero A Galarreta DJ Herreras JM
author_sort	Carre&ntilde;o E
title	Update on twice-daily bromfenac sodium sesquihydrate to treat postoperative ocular inflammation following cataract extraction
title_short	Update on twice-daily bromfenac sodium sesquihydrate to treat postoperative ocular inflammation following cataract extraction
title_full	Update on twice-daily bromfenac sodium sesquihydrate to treat postoperative ocular inflammation following cataract extraction
title_fullStr	Update on twice-daily bromfenac sodium sesquihydrate to treat postoperative ocular inflammation following cataract extraction
title_full_unstemmed	Update on twice-daily bromfenac sodium sesquihydrate to treat postoperative ocular inflammation following cataract extraction
title_sort	update on twice-daily bromfenac sodium sesquihydrate to treat postoperative ocular inflammation following cataract extraction
publisher	Dove Medical Press
publishDate	2012
url	https://doaj.org/article/76a71724af06481d95da14649eac9ae1
work_keys_str_mv	AT carreampntildeoe updateontwicedailybromfenacsodiumsesquihydratetotreatpostoperativeocularinflammationfollowingcataractextraction AT porteroa updateontwicedailybromfenacsodiumsesquihydratetotreatpostoperativeocularinflammationfollowingcataractextraction AT galarretadj updateontwicedailybromfenacsodiumsesquihydratetotreatpostoperativeocularinflammationfollowingcataractextraction AT herrerasjm updateontwicedailybromfenacsodiumsesquihydratetotreatpostoperativeocularinflammationfollowingcataractextraction
_version_	1718403871453216768

Update on twice-daily bromfenac sodium sesquihydrate to treat postoperative ocular inflammation following cataract extraction

Ejemplares similares